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The current standard treatment for rectal cancer is based on a multimodality approach with
preoperative radiochemotherapy in advanced cases and complete surgical removal through
total mesorectal excision (TME). The most frequent surgical approach is traditional open
surgery, as laparoscopic TME requires high technical skill, a long learning curve, and is
not widespread, still being confined to centers with great experience in minimally invasive
techniques. Nevertheless, in several studies, the laparoscopic approach, when compared
to open surgery, has shown some better short-term clinical outcomes and at least compa-
rable oncologic results. Robotic surgery for the treatment of rectal cancer is an emerging
technique, which could overcome some of the technical difficulties posed by standard
laparoscopy, but evidence from the literature regarding its oncologic safety and clinical
outcomes is still lacking. This brief review analyses the current status of minimally inva-
sive surgery for rectal cancer therapy, focusing on oncologic safety and the new robotic
approach.
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INTRODUCTION
The main innovations over the last decades for the treatment
of locally advanced rectal cancer have been multimodal pre-
operative treatments with preoperative radiochemotherapy and
the optimization of surgical technique with the introduction of
TME (1, 2).
Total mesorectal excision changed the technique of rectal resec-
tion and confirmed the importance of maintaining the integrity of
the mesorectal fascia to improve oncologic outcomes. As a result,
in some series, TME surgery has been demonstrated to decrease
the rate of local recurrence (LR) to <10%, when compared to
conventional dissection (3).
Nowadays, TME surgery preceded by neoadjuvant chemoradi-
ation is considered as the standard of care for locally advanced
rectal cancer (4). The opportunity to perform a minimally inva-
sive TME is correlated to the clinical benefits demonstrated by
minimally invasive surgery (MIS) (5). Laparoscopic colectomy is
a feasible and oncologically safe procedure with an increasing dif-
fusion, but minimally invasive TME is less adopted because of its
technical difficulties (6).
Robotic surgery is a new emerging technique that seems to
overcome some difficulties of standard laparoscopic approach in
the pelvis, and its use in rectal cancer is under evaluation (7, 8).
This mini review summarizes the current role of MIS in rectal
resections for cancer also evaluating the recent developments of
robotic technique.
LAPAROSCOPIC SURGERY IN RECTAL CANCER
The widespread adoption of MIS in several surgical proce-
dures is correlated with some short-term better clinical outcomes
achievable by this technique when compared to traditional open
surgery.
In the surgical treatment of cancer, the diffusion of MIS has
been slower than in other benign diseases, due to the necessity to
confirm the oncologic safety of the technique (9).
Nowadays, long-term oncologic results of laparoscopic vs.
open surgery for colon cancer have been established by several
randomized clinical trials (10–12).
These results have overcome the initial concern about onco-
logic safety and port-site recurrence of MIS for cancer (13, 14),
but technical difficulties of laparoscopic resection and the conse-
quent long learning curve have limited its dissemination outside
specialized centers (15–17).
Technical difficulties are increased in laparoscopic rectal resec-
tion because of the anatomy of the pelvis, where it is difficult to
manipulate the straight laparoscopic instruments. Therefore, rec-
tal MIS is even less widespread than laparoscopic colectomy (18).
The diffusion of laparoscopic colonic surgery has increased
in recent years by specific educational and training programs,
but mainly in academic and high-volume hospitals (18, 19). The
most frequently performed procedures are the less difficult, such
as sigmoidectomy for benign diseases and right colectomies with
extracorporeal anastomosis (6). In the United States, laparoscopic
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rectal resection did not make up 20% of the overall rectal resec-
tions and its conversion rate to open surgery is still high (46.2%),
without any significant improvement in recent years (18). For this
reason, still in 2012, the National Comprehensive Cancer Network
guidelines for treatment in rectal cancer recommended the use
of laparoscopy for rectal cancer treatment only within a study
protocol and in highly specialized centers (4).
Three randomized controlled trials evaluated feasibility and
oncologic safety of laparoscopic TME (20–22). The first report
of the CLASICC trial comparing laparoscopic to open surgery
and including rectal resections (20), raised a concern about
an increased positivity of the circumferential resection margin
(CRM) among patients in the laparoscopic group, but this result
was not translated into any significant difference compared to
open surgery in terms of survival rates after 6 years of follow-
up. (23). The COREAN trial (21) compared laparoscopy to open
surgery in rectal cancer after neoadjuvant chemoradiotherapy, and
although participating surgeons had greater experience in laparo-
scopic surgery than did surgeons participating in the CLASICC
trial, the differences in percentage of CRM positivity were simi-
lar in the two groups: 4.1% in the open group and 2.9% in the
laparoscopic group. The recently published COLOR II study (22),
also comparing laparoscopic to open surgery in rectal resections,
did not reveal any significant difference between the two proce-
dures in terms of morbidity, mortality, and complication rates,
and confirmed the benefits of the minimally invasive approach as
less blood loss, more rapid recovery of bowel function, and shorter
hospital stay.
Although the participating surgeons were all experts in laparo-
scopic surgery, the conversion rate to open surgery was still high
(16%), confirming the technical challenges of laparoscopic rec-
tal surgery. Interestingly, in contrast to the CLASICC trial, in the
COLOR II study, a proportion of higher CRM positivity was found
in the open rather than in the laparoscopic arm, in the distal rec-
tal cancer subgroup (22 vs. 9%, p= 0.014) (Table 1). However,
the number of patients is too low to consider these data conclu-
sive and the trial has a possible bias of selection, because patients
with a T4 or a T3 tumor within 2 mm of endopelvic fascia were
excluded (22).
The conversion of a laparoscopic to an open procedure is a
critical issue, since it has been demonstrated to lead to an increase
in complication rate, length of hospital stay, overall costs, and in
some studies also to have a negative impact on LR and overall
survival rates (12, 24).
Our experience in laparoscopic rectal resection as a high-
volume surgical center is comparable to that reported in the
literature. In a prospective analysis of more than 100 laparoscopic
rectal resections with a mean follow-up of 35.8 months, oncologic
results were not inferior to those of standard open surgery, but the
technique was considered demanding, because of the high per-
centage of conversion rate to open (18.7%) and the prolonged
operating time (mean operating time, 278 min). The conclusion
of that study was that laparoscopic rectal resection should be per-
formed in specialized centers by teams experienced in laparoscopic
surgery (17).
THE EMERGING ROLE OF ROBOTIC-ASSISTED SURGERY
Robotic surgery is an emerging minimally invasive technique. The
robotic system is composed of three integrated elements: a sur-
geon console, a patient-side cart with interactive robotic arms
connected to the surgical instruments and a video tower with
the system processors, and a high-definition three-dimensional
vision system. The optical system provides a high definition, three-
dimensional vision, and surgical instruments are provided for
seven degrees of freedom and for a range of motion greater than
the human wrist; this enables extremely fine and precise man-
ual dexterity. Therefore, robotics seems to have the potential to
overcome some of the technical difficulties of traditional laparo-
scopic surgery, allowing high-quality maneuvers to be performed
in narrow spaces such as the pelvic cavity, and using a third arm
instrument as a fixed retractor, improving vision and stability in
restricted spaces. The results available on robotic rectal resections
are limited, originating mainly from single-center experiences, but
the interest of the scientific community is high as demonstrated by
the several meta-analyses already published despite the lack of evi-
dence (25–29). In all of these studies, the only significant data was
that robotic surgery resulted in a lower percentage of conversion
to open surgery, compared to the laparoscopic groups. Regard-
ing short-term clinical and oncologic outcomes, no significant
differences were found between laparoscopy and robotic surgery,
as reported in Table 2 and Table 3. Few studies have compared
robotic surgery to standard treatment of open resection, and in
these studies robotic surgery resulted oncologically safe in terms
of length of specimen, resection margins, and number of lymph
nodes harvested (37, 38).
One of the main concerns about robotic technology is the
high costs of the purchase and maintenance of the equipment.
Baek et al. (39) showed increased costs in robotic rectal resection
Table 1 | Comparison of circumferential resection margin positivity in open and laparoscopic total mesorectal excision (TME).
Overall (%) AR (%) APR (%)
Open LAP p Open LAP p Open LAP p
CLASICC (20) 14 16 0.8 6 12 0.19 26 20 1.0
COREAN (21) 4.1 2.9 0.7 3.4 2.7 1.0 8.3 5.3 1.0
COLOR II (22) distal rectal cancer 10 10 0.8 22 9 0.01 25 8 0.003
AR, anterior resection; APR, abdominoperineal resection; LAP, laparoscopic resection; p, p value.
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Table 2 | Oncologic results of laparoscopic and robotic surgery for rectal cancer.
Harvested lymph nodes (n) p Distal resection margin (cm) p Positive CRM (%) p
ROB LAP ROB LAP ROB LAP
Park et al. (30) 17.3 14.2 0.06 2.1 2.3 ns 4.9 3.7 0.5
Kim and Kang (31) 14.7 16.6 ns 2.7 2.6 0.09 3 2 ns
Kwak et al. (32) 20 21 0.7 2.2 2.8 0.8 1.7 0 >0.9
Baek et al. (33) 13 16 0.07 3.6 3.8 0.6 2.4 4.9 1
Bianchi et al. (34) 18 17 0.7 2 2 1.0 0 4 0.9
Baik et al. (35) 18.4 18.7 0.8 4 3.6 0.4 7 8 0.7
Patriti et al. (36) 10.3 11.2 >0.05 2.1 4.5 >0.05 0 0 ns
Meta analysis [Memon et al. (25)].
CRM, circumferential resection margin; ROB, robotic resection; LAP, laparoscopic resection; p, p value.
Table 3 | Clinical results of laparoscopic and robotic surgery for rectal cancer.
Conversions (%) p Hospital stay (days) p Complications (%) p
ROB LAP ROB LAP ROB LAP
Park et al. (30) 0 0 1 9.9 9.4 0.5 29.3 23.2 0.4
Kim and Kang (31) 2 3 1 11.7 14.4 0.006 20 27 0.4
Kwak et al. (32) 0 3.4 0.4 NA NA 32 27 ns
Baek et al. (33) 7.3 22 0.116 6.5 6.6 0.8 22 27 1
Bianchi et al. (34) 0 4 NA 6.5 6 0.4 16 24 0.5
Baik et al. (35) 0 10.5 0.013 5.7 7.6 0.001 10.7 19.3 0.025
Patriti et al. (36) 0 19 <0.05 11.9 9.6 >0.05 30.6 18.9 >0.05
Meta analysis [Memon et al. (25)].
ROB, robotic resection; LAP, laparoscopic resection; p, p value; NA, not available; ns: not significant.
compared to those in the standard laparoscopic procedure, with a
significantly lower hospital profit in the robotic group.
Another emerging problem is the appropriate use of the tech-
nology by low volume centers/surgeons, in fact a higher number
of complications are reported by Keller et al. (40) in the low vol-
ume users when compared to middle- and high-volume centers
and surgeons.
Recent studies have demonstrated a superiority of robotic rectal
resection in recovery of urinary voiding and sexual function (41,
42), but these results need to be confirmed by larger randomized
studies.
At present, two multicentre studies comparing robotic to
laparoscopic TME (ROLARR and COLRAR) are ongoing and
results are awaited to better define the role of robotic rectal surgery
(43, 44).
In 2008, we launched a robotic program in rectal cancer,
extended to anesthesiologists and operating room nurses. The
only criterion of choice between laparoscopic and robotic-assisted
resection was the availability of the robotic system. The first 25
robotic-TME procedures were compared with 25 well-matched
laparoscopic procedures, and the results were similar in terms of
clinical and oncologic outcomes (34). In the robotic group, no
patients were converted to open, while in the laparoscopic group,
the conversion rate was 4% (1/25). Operating time was similar
in the two groups (240 min laparoscopic TME, 237 min robotic-
TME) and was not modified in the robotic-TME group during
time (Table 4).
DISCUSSION AND PERSONAL REMARKS
Minimally invasive surgery is considered one of the most impor-
tant innovations in surgical technique for the last 25 years. One of
the goals of surgical oncology is the possibility to reduce the inva-
siveness of surgery maintaining or further improving the results of
traditional open surgery. Therefore, minimally invasive techniques
have been applied to oncologic surgery since the end of 90s, on the
basis of the good clinical results obtained by laparoscopic surgery
in some benign diseases (45, 46).
The first colonic resection was described in 1991 (47) and a lot
of concern raised on the oncologic safety of the procedure, in terms
of length of the specimen removed and number of lymphnodes
harvested (48). Nevertheless, the way of minimally invasiveness
seemed to the great majority of surgeons to be the right way to fol-
low and since then several RCTs have been published comparing
laparoscopic to open colectomy (20, 49–52).
Since the first study of Lacy et al. published in 2002 (53), all
the following trials comparing laparoscopic to open colectomy
demonstrated the oncologic safety of laparoscopy, then confirmed
also as long-term survival rates (10–12).
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Table 4 | Clinical and oncologic outcomes of 50 minimally invasive
total mesorectal excision (TME).
ROB LAP p
Complications (%) 16 24 0.5
Median (range) operating
time (min)
240 (170–420) 237 (170–545) 0.2
Conversions n (%) 0 (0) 1 (4)
Median (range) first bowel
movements (days)
2 (1–7) 3 (1–4) 0.5
Median (range) hospital
stay (days)
6.5 6 0.4
Median (range) lymph
nodes/patient (n)
18 17 0.7
Median (range) distal
resection margin (cm)
2 2 1.0
CRM positivity n (%) 0/25 (0) 1/25 (4) 0.9
Bianchi et al. (34).
ROB, robotic resection; LAP, laparoscopic resection; p, p value; CRM, circumfer-
ential resection margin.
Laparoscopy was further associated to some short-term advan-
tages as: less pain, less intraoperative blood loss, shorter duration
of postoperative ileus, shorter hospital stay, improved pulmonary
function, decrease of total and local morbidity, quicker recovery,
and less inflammatory factors activation (5, 54).
On the basis of the results of these RCTs, the conclusion of a
Cochrane review in 2005 was that “laparoscopic approach should
be preferred in patients suitable for this approach to colectomy”
(5). Nevertheless, the diffusion of laparoscopic colectomy has been
slower and more difficult than supposed, probably due to the long
learning curve and to the absence of well-planned educational
programs.
Only in the last few years, the trend was slightly inverted with an
increase of laparoscopic surgery in colon resection, even if mainly
in selected cases and in specialized centers (19).
The role of a planned educational program is crucial to improve
the safety of the procedure and to increase its spread, as reported by
the results of the Dutch Surgical Colorectal Audit (55), although
in this report the percentage of conversions to open surgery is
still 15%.
Regarding minimally invasive rectal cancer surgery, we are a
step back to laparoscopic colectomy, either in terms of diffusion
of the procedure either in terms of level of evidence (56).
The available RCTs demonstrate the feasibility, safety, and onco-
logic adequacy of minimally invasive TME, but long-term high
evidence data come essentially from the CLASICC study, where
the majority of participating surgeons were low experienced (12).
The learning curve of minimally invasive TME is longer and
steeper than for laparoscopic colectomy and the percentage of
conversions to open surgery is still high, confirming the tech-
nical difficulties of the procedure and still the necessity of an
accurate selection of patients (57). For example, one of the
most difficult steps of the procedure is distal resection of the
rectum, and robotic assistance could be helpful in the expo-
sure of the distal pelvis, facilitating the stapler positioning for
transection.
For these reasons, the diffusion of laparoscopic TME in the last
years has been low and without a trend to increase. Nevertheless,
the post operative short-term advantages of the minimally invasive
approach are confirmed, as for laparoscopic colectomies, there-
fore, an increasing diffusion of minimally invasive TME should be
desirable.
Robotics is a technology, which helps minimally invasive pelvic
surgery and probably also rectal resections. It is our opinion that
robotic assistance with virtual simulators or dual console proctor-
ing systems could be important devices to facilitate the adoption
of minimally invasive rectal surgery.
Although the results available on robotic surgery are still few,
robotic assistance seems to reduce the percentage of conversions to
open surgery among expert surgeons and is promising as a method
to attenuate the learning curve of a well-conducted TME (58). At
the moment, the robotic system has higher costs than laparoscopy
and its use should be planned within the remit of clearly defined
educational program, preferably in a hospital conducting mid-
dle/high volumes of MIS and colorectal procedures, in order to
avoid an increase in complication rates.
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